A population-based case-control teratologic study of oral erythromycin treatment during pregnancy

E. Czeizel, M. Rockenbauer, Henrik T. Sørensen, Jørn Olsen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The objective of the study was to evaluate the human teratogenic potential of oral erythromycin treatment during pregnancy in the population- based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 172 (0.5%) had received erythromycin, while of 22,865 pregnant women who had newborns or fetuses with congenital abnormalities, 113 (0.5%) had been treated with erythromycin (crude OR with 95% CI = 1.1, 0.9-1.4). The case-control pair analysis did not indicate a teratogenic potential of erythromycin during the second through third months of gestation, i.e., in the critical period for most major congenital abnormalities. The frequency of maternal erythromycin treatments during the second-third months of pregnancy was also not higher in different congenital abnormality groups compared with the rate of the total control group as referent. Thus, treatment with oral erythromycin during pregnancy did not present detectable teratogenic risk to the fetus.

Original languageEnglish
Pages (from-to)531-536
Number of pages6
JournalReproductive Toxicology
Volume13
Issue number6
DOIs
Publication statusPublished - Nov 1999

Fingerprint

Erythromycin
Case-Control Studies
Pregnancy
Population
Pregnant Women
Fetus
Therapeutics
Newborn Infant
Control Groups
Population Control
Population Groups
Mothers

Keywords

  • Case- control analysis
  • Congenital abnormalities
  • Erythromycin
  • Human teratogenic potential

ASJC Scopus subject areas

  • Toxicology

Cite this

A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. / Czeizel, E.; Rockenbauer, M.; Sørensen, Henrik T.; Olsen, Jørn.

In: Reproductive Toxicology, Vol. 13, No. 6, 11.1999, p. 531-536.

Research output: Contribution to journalArticle

@article{938f773668ef4af3a62e4562aa7d6110,
title = "A population-based case-control teratologic study of oral erythromycin treatment during pregnancy",
abstract = "The objective of the study was to evaluate the human teratogenic potential of oral erythromycin treatment during pregnancy in the population- based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 172 (0.5{\%}) had received erythromycin, while of 22,865 pregnant women who had newborns or fetuses with congenital abnormalities, 113 (0.5{\%}) had been treated with erythromycin (crude OR with 95{\%} CI = 1.1, 0.9-1.4). The case-control pair analysis did not indicate a teratogenic potential of erythromycin during the second through third months of gestation, i.e., in the critical period for most major congenital abnormalities. The frequency of maternal erythromycin treatments during the second-third months of pregnancy was also not higher in different congenital abnormality groups compared with the rate of the total control group as referent. Thus, treatment with oral erythromycin during pregnancy did not present detectable teratogenic risk to the fetus.",
keywords = "Case- control analysis, Congenital abnormalities, Erythromycin, Human teratogenic potential",
author = "E. Czeizel and M. Rockenbauer and S{\o}rensen, {Henrik T.} and J{\o}rn Olsen",
year = "1999",
month = "11",
doi = "10.1016/S0890-6238(99)00046-5",
language = "English",
volume = "13",
pages = "531--536",
journal = "Reproductigve Toxicoloy",
issn = "0890-6238",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - A population-based case-control teratologic study of oral erythromycin treatment during pregnancy

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Sørensen, Henrik T.

AU - Olsen, Jørn

PY - 1999/11

Y1 - 1999/11

N2 - The objective of the study was to evaluate the human teratogenic potential of oral erythromycin treatment during pregnancy in the population- based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 172 (0.5%) had received erythromycin, while of 22,865 pregnant women who had newborns or fetuses with congenital abnormalities, 113 (0.5%) had been treated with erythromycin (crude OR with 95% CI = 1.1, 0.9-1.4). The case-control pair analysis did not indicate a teratogenic potential of erythromycin during the second through third months of gestation, i.e., in the critical period for most major congenital abnormalities. The frequency of maternal erythromycin treatments during the second-third months of pregnancy was also not higher in different congenital abnormality groups compared with the rate of the total control group as referent. Thus, treatment with oral erythromycin during pregnancy did not present detectable teratogenic risk to the fetus.

AB - The objective of the study was to evaluate the human teratogenic potential of oral erythromycin treatment during pregnancy in the population- based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 172 (0.5%) had received erythromycin, while of 22,865 pregnant women who had newborns or fetuses with congenital abnormalities, 113 (0.5%) had been treated with erythromycin (crude OR with 95% CI = 1.1, 0.9-1.4). The case-control pair analysis did not indicate a teratogenic potential of erythromycin during the second through third months of gestation, i.e., in the critical period for most major congenital abnormalities. The frequency of maternal erythromycin treatments during the second-third months of pregnancy was also not higher in different congenital abnormality groups compared with the rate of the total control group as referent. Thus, treatment with oral erythromycin during pregnancy did not present detectable teratogenic risk to the fetus.

KW - Case- control analysis

KW - Congenital abnormalities

KW - Erythromycin

KW - Human teratogenic potential

UR - http://www.scopus.com/inward/record.url?scp=0033226610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033226610&partnerID=8YFLogxK

U2 - 10.1016/S0890-6238(99)00046-5

DO - 10.1016/S0890-6238(99)00046-5

M3 - Article

C2 - 10613401

AN - SCOPUS:0033226610

VL - 13

SP - 531

EP - 536

JO - Reproductigve Toxicoloy

JF - Reproductigve Toxicoloy

SN - 0890-6238

IS - 6

ER -